Downloaded 55 times
Uploaded byMohammed Fathy
Prognostic & predictive factors of breast cancer
1) Prognostic factors provide information about a patient's outcome without treatment, while predictive factors provide information about how a patient may respond to a specific treatment. 2) Many clinical factors, pathological features, tissue markers, and genomic expression profiles can provide prognostic and predictive information for breast cancer patients. 3) Key prognostic factors include age, tumor stage, tumor size, nodal involvement, histological grade, hormone receptor status, and intrinsic subtypes. Predictive factors include hormone receptor and HER2 status.
In this document
Powered by AI
Overview of prognostic and predictive factors impacting breast cancer outcomes and treatment responses.
Factors like age and net survival percentages in newly diagnosed non-metastatic breast cancer patients.
The influence of menopausal status on chemotherapy-induced amenorrhea and treatment outcomes.
Discussion on the role of race as a factor in breast cancer patient demographics.
The impact of cigarette smoking, mammographic features, and breast density on breast cancer prognosis.
Evaluation of tumor stage and its correlation with breast cancer prognosis.
Insights into tumor size as a pathological feature affecting breast cancer staging.
The assessment of nodal involvement and its implications for prognosis.
Understanding the characteristics and implications of metastatic breast cancer.
Analysis of multiple aspects of tumor morphology associated with breast cancer.
The importance of peritumoral lymphovascular invasion in breast cancer prognosis.
Evaluation of hormone receptors and their role in breast cancer management and prognosis.
Exploration of genetic heterogeneity and gene testing tools like Heat Maps.
Description of genomic clusters and intrinsic lists in breast cancer contexts.
Analysis of different intrinsic subtypes, their characteristics, and clinical outcomes.
Discussion of genomic expression profiles and their relation to breast cancer recurrence.
Information on recurrence scores like Oncotype Dx and their significance in treatment choices.
Details on the EP & Epclin score relevant for breast cancer recurrence prediction.
Importance of the Breast Cancer Index in evaluating recurrence risk.
Details on the ROR score and its application in recurrence risk evaluation.
Insights into the significance of MammaPrint in assessing breast cancer recurrence.
Discussions on tests like Genomic Grade Index and their relevance in diagnosis.
Analysis of various markers including Ki-67 and their roles in tumor proliferation.
Examination of urokinase and other markers that reflect tumor invasion and metastasis.
Insight into various forms of tumor markers in circulation and their diagnostic utility.
More Related Content
![Molecular biology of breast cancer [autosaved]](https://cdn.slidesharecdn.com/ss_thumbnails/molecularbiologyofbreastcancerautosaved-191226181803-thumbnail.jpg?width=640&height=640&fit=bounds)
Similar to Prognostic & predictive factors of breast cancer
Prognostic & predictive factors of breast cancer
- 1. Prognostic & Predictive factorsof Breast Cancer Dr. MohammedFathyBayomy Lecturer of ClinicalOncology ZagazigUniversity
- 2. Definition Prognostic factor Parameter XWithout Treatment Breast Cancer Population (Without X) (With X) Outcome 50% with Unfavorable outcome 50% with Favorable outcome 20% with Unfavorable outcome 80% with Favorable outcome (Positive or Negative prognostic factor)
- 3. Definition Predictive factor Parameter XTreatmentBreast Cancer Population (Without X) (With X) Response 90% with response 10% without response 10% with response 90% without response (Positive or negative predictive factor)
- 4. Definition Prognostic & Predictivefactor Parameter X Receive or not Receive treatmentBreast Cancer Population (Without X) (With X) Response 90% with response 10% without response 10% with response 50% with Unfavorable outcome 50% with Favorable outcome 20% with Unfavorable outcome 80% with Favorable outcome 90% without response
- 5. Newly Diagnosed Non-MetastaticBreast Cancer Prognostics Clinical Factors Gene Expression Profile Patient Pathology Tissue Markers
- 6. Patient features Age Net Survival(%) Age Range Women 15–39 84.9 40–49 90.0 50–59 91.2 60–69 92.4 70–79 83.0 80–99 70.3 Five-Year Net Survival by Age, Women, England Breast Cancer (C50): 2009-2013 1 out of 5
- 7.
- 8.
- 9.
- 10. Patient features Age 5 outof 5 Time Trend
- 11. Patient features Menopausal Status 1out of 2 Age is a critical factor influencing the onset and persistence of chemotherapy-induced amenorrhea.
- 12. Patient features Menopausal Status 2out of 2 Chemotherapy induced amenorrhea improve breast cancer treatment outcome.
- 13.
- 14.
- 15.
- 16. Patient features Mammographic features:screening 1 out of 1
- 17. Patient features Mammographic features:breast density 1 out of 1
- 18. Patient features Mammographic features:multiplicity 1 out of 1
- 19.
- 20.
- 21.
- 22. Pathological features Tumor Size(T) 1 out of 3
- 23. Pathological features Tumor Size(T) 2 out of 3
- 24. Pathological features Tumor Size(T) 3 out of 3
- 25.
- 26.
- 27.
- 28.
- 29.
- 30.
- 31.
- 32.
- 33.
- 34. Pathological features Peritumoral lymphovascularinvasion (PLVI) 1 out of 2
- 35. Pathological features Peritumoral lymphovascularinvasion (PLVI) 2 out of 2
- 36.
- 37.
- 38.
- 39.
- 40.
- 41.
- 42.
- 43. Genomic Profiles Gene Testing 1out of 1 Heat Map
- 44. Genomic Profiles Gene Testing 1out of 1
- 45. Genomic Profiles Gene Cluster 1out of 3
- 46. Genomic Profiles Gene Cluster 2out of 3
- 47. Genomic Profiles Gene Cluster 3out of 3
- 48.
- 49.
- 50.
- 51.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
- 68.
- 69.
- 70.
- 71. Express ER Most common. Luminal A possess a higher expression of the ER and oestrogen-associated genes ESR1, GATA3 and FOXA1 Do not express HER2/neu Ki-67 proliferation index- low Luminal A tumours are associated with a better prognosis Genomic Profiles Intrinsic Subtypes Luminal A
- 72. Express ER Variable HER2/neu expression Increased frequency of TP53 mutations Ki-67 proliferation index- high Luminal B tumours are associated with worse prognosis compared to Luminal A Genomic Profiles Intrinsic Subtypes Luminal B
- 73. Increased expressionof genes located in the same region on chromosome 17q: human epidermal growth factor receptor 2 (ERBB2) and growth factor receptor bound protein 7 (GRB7). Associated with a high histological grade, low expression of ER and PR. Poor clinical outcome. Genomic Profiles Intrinsic Subtypes HER2 Enriched
- 74. Hormone receptor(ER and PR) and HER2/neu receptor negative. Expression of genes associated with myoepithelial cells: KRT5 (keratin 5), KRT17 (keratin 17), CNN1 (calponin 1), CAV1 (caveolin) and LAMB1 (laminin). Aggressive with a poorer disease-free and overall survival than the other breast cancer subtypes. Genomic Profiles Intrinsic Subtypes ER-negative subtypes
- 75.
- 76.
- 77.
- 78.
- 79.
- 80.
- 81.
- 82.
- 83.
- 84. Genomic Expression Profiles 1out of 3
- 85. Genomic Expression Profiles 2out of 3
- 86. Genomic Expression Profiles 3out of 3
- 87. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 1 out of 7
- 88. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 2 out of 7
- 89. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 3 out of 7
- 90. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 4 out of 7
- 91. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 5 out of 7
- 92. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 6 out of 7
- 93. Genomic Expression Profiles RecurrenceScore (RS) Oncotype Dx 7 out of 7
- 94. Genomic Expression Profiles EP& Epclin score - Endopredict 1 out of 5
- 95. Genomic Expression Profiles 2out of 5 EP & Epclin score - Endopredict Epclin score = EP score + Tumor size + N
- 96. Genomic Expression Profiles 3out of 5 EP & Epclin score - Endopredict
- 97. Genomic Expression Profiles 4out of 5 EP & Epclin score - Endopredict
- 98. Genomic Expression Profiles 5out of 5 EP & Epclin score - Endopredict
- 99. Genomic Expression Profiles 1out of 3 Breast Cancer Index (BCI)
- 100. Genomic Expression Profiles 2out of 3 Breast Cancer Index (BCI)
- 101. Genomic Expression Profiles 2out of 3 Breast Cancer Index (BCI)
- 102. Genomic Expression Profiles 1out of 2 Risk of Recurrence (ROR) score - PAM50 (Prosigna)
- 103. Genomic Expression Profiles 2out of 2 Risk of Recurrence (ROR) score - PAM50 (Prosigna)
- 104. Genomic Expression Profiles 1out of 2 70-Gene Breast Cancer Recurrence Assay - MammaPrint MammaPrint Index (MPI)
- 105. Genomic Expression Profiles 1out of 2 70-Gene Breast Cancer Recurrence Assay - MammaPrint
- 106. Genomic Expression Profiles 1out of 1 80-Gene Molecular subtyping Assay - BluePrint
- 107. Genomic Expression Profiles 1out of 1 Genomic Grade Index (GGI) - MapQuant Dx
- 108. Genomic Expression Profiles 1out of 1 IHC4 Test
- 109. Genomic Expression Profiles 1out of 7
- 110. Genomic Expression Profiles 2out of 7
- 111. Genomic Expression Profiles 3out of 7
- 112. Genomic Expression Profiles 4out of 7
- 113. Genomic Expression Profiles 5out of 7
- 114. Genomic Expression Profiles 6out of 7
- 115. Genomic Expression Profiles 7out of 7
- 116. Markers of Proliferation MitoticCount S-phase fraction (SPF) 1 out of 2
- 117. Markers of Proliferation Ki-67 2out of 2
- 118. Urokinase Plasminogen Activator(uPA) 1 out of 2
- 119. Urokinase Plasminogen Activator(uPA) 2 out of 2
- 120. Measurement of p53 1out of 1
- 121. Measurement of HER2-ECD 1out of 1
- 122. Other markers ofinvasion & metastasis 1 out of 1
- 123. Disseminated Tumor Cells(DTCs) 1 out of 1
- 124. Circulating Tumor Cells(CTCs) 1 out of 1
- 125. Circulating Tumor DNA(ctDNA) 1 out of 1